Results 41 to 50 of about 22,252 (260)
Quantitative Analysis of Candida Cell Wall Components by Flow Cytometrywith Triple-Fluorescence Staining [PDF]
, 2017 This work was supported by the European Commission within the FP7 Framework Programme [Fungitect-Grant No 602125]. We also thank Thomas Sauer, Vienna Biocenter Campus (VBC), Austria, for technical support at the FACS facility of the MFPL, Karl Kuchler ...
Gow, N +5 more
core +1 more source
Resistance of Candida to azoles and echinocandins worldwide.
Clinical Microbiology and Infection, 2019 BACKGROUND Recently there has been an increase in Candida infections worldwide. A handful of species in the genus Candida are opportunistic pathogens and have been known to cause infections in immunocompromised or otherwise impaired hosts.
K. E. Pristov, M. Ghannoum
semanticscholar +1 more source
Antibiotics, 2021 Candida glabrata is one of the most prevalent causative pathogens of invasive candidiasis, and multidrug-resistant strains are emerging. We identified two clinical isolates of C. glabrata, BMU10720 and BMU10722 sequentially isolated from one patient with
Qiqi Wang +9 more
doaj +1 more source
Candida auris, what do paediatricians need to know? [PDF]
, 2018 AW is supported by the Wellcome Trust Strategic Award (grant 097377) and the MRC Centre for Medical Mycology (grant MR/N006364/1) at the University of Aberdeen.Peer reviewedPublisher ...
Warris, Adilia
core +1 more source
Echinocandins: structural diversity, biosynthesis, and development of antimycotics
Applied Microbiology and Biotechnology, 2020 Echinocandins are a clinically important class of non-ribosomal antifungal lipopeptides produced by filamentous fungi. Due to their complex structure, which is characterized by numerous hydroxylated non-proteinogenic amino acids, echinocandin antifungal ...
Wolfgang Hüttel
semanticscholar +1 more source
Journal of Fungi, 2021 Invasive candidiasis is known to be one of the most common healthcare-associated complications and is caused by several Candida species. First-line drugs, particularly echinocandins, are effective, but there are increasing reports of resistance to these ...
L. Trovato +8 more
semanticscholar +1 more source
Micafungin: A New Echinocandin [PDF]
Clinical Infectious Diseases, 2006 Micafungin, a potent inhibitor of 1,3-beta-D-glucan synthase, has become the second available agent in the echinocandins class that is approved for use in clinical practice. This agent shares with caspofungin an identical spectrum of in vitro activity against Candida albicans, non-albicans species of Candida, and Aspergillus species, as well as several
P H, Chandrasekar, J D, Sobel
openaire +2 more sources
Antimicrobial activity, synergism and inhibition of germ tube formation by Crocus sativus-derived compounds against Candida spp [PDF]
, 2016 The limited arsenal of synthetic antifungal agents and the emergence of resistant Candida strains have prompted the researchers towards the investigation of naturally occurring compounds or their semisynthetic derivatives in order to propose new ...
ANGIOLELLA, Letizia +4 more
core +2 more sources
Stimulation of chitin synthesis rescues Candida albicans from echinocandins.
PLoS Pathogens, 2008 Echinocandins are a new generation of novel antifungal agent that inhibit cell wall beta(1,3)-glucan synthesis and are normally cidal for the human pathogen Candida albicans. Treatment of C.
Louise A Walker +5 more
doaj +1 more source
First hospital outbreak of the globally emerging Candida auris in a European hospital [PDF]
, 2016 Background: Candida auris is a globally emerging multidrug resistant fungal pathogen causing nosocomial transmission. We report an ongoing outbreak of C. auris in a London cardio-thoracic center between April 2015 and July 2016.
Abdolrasouli, A +11 more
core +2 more sources